A host-directed macrocyclic peptide therapeutic for MDR gram negative bacterial infections

Justin B. Schaal, Yoshihiro Eriguchi, Dat Q. Tran, Patti A. Tran, Chase Hawes, Anthony E. Cabebe, Kaitlyn Pike, Katie Trinh, André J. Ouellette, Michael E. Selsted

研究成果: ジャーナルへの寄稿学術誌査読

4 被引用数 (Scopus)


The emergence of infections by carbapenem resistant Enterobacteriaceae (CRE) pathogens has created an urgent public health threat, as carbapenems are among the drugs of last resort for infections caused by a growing fraction of multi-drug resistant (MDR) bacteria. There is global consensus that new preventive and therapeutic strategies are urgently needed to combat the growing problem of MDR bacterial infections. Here, we report on the efficacy of a novel macrocyclic peptide, minimized theta-defensin (MTD)-12813 in CRE sepsis. MTD12813 is a theta-defensin inspired cyclic peptide that is highly effective against CRE pathogens K. pneumoniae and E. coli in vivo. In mouse septicemia models, single dose administration of MTD12813 significantly enhanced survival by promoting rapid host-mediated bacterial clearance and by modulating pathologic cytokine responses, restoring immune homeostasis, and preventing lethal septic shock. The peptide lacks direct antibacterial activity in the presence of mouse serum or in peritoneal fluid, further evidence for its indirect antibacterial mode of action. MTD12813 is highly stable in biological matrices, resistant to bacterial proteases, and nontoxic to mice at dose levels 100 times the therapeutic dose level, properties which support further development of the peptide as a first in class anti-infective therapeutic.

ジャーナルScientific reports
出版ステータス出版済み - 12月 2021

!!!All Science Journal Classification (ASJC) codes

  • 一般


「A host-directed macrocyclic peptide therapeutic for MDR gram negative bacterial infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。